Spore-based probiotic supplementation and control of endotoxemia in dogs
By applying probiotic compositions of Bacillus subtilis, Bacillus licheniformis and P. lactococcus lactate to dogs, the problems of endotoxinemia and digestive disorders were solved in dogs, and the reduction of endotoxin levels and improvement of digestive health were achieved.
Patent Information
- Application Number
- CN202080064613.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-16
- Filing Date
- 2020-09-16
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-09-16
AI Technical Summary
Endotoxinemia and digestive disorders exist in dogs, and the prior art is difficult to effectively reduce endotoxinemia and improve the digestive process.
Probiotic compositions containing Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici were administered to dogs in oral capsule form to reduce endotoxinemia and improve digestive health.
It significantly reduces the endotoxinemia level in dogs, improves the digestive process, improves the digestibility of feed, reduces the amount of feces and bloating, enhances immune function, and improves overall health.
Smart Images

Figure CN114423442B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to methods of administering a probiotic composition comprising Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici to dogs to reduce endotoxemia and improve digestive processes and related methods. Background Art
[0002] In many species, including domesticated mammals, companion animals, and pets, interactions between the gut microbiota and the host play an important role in the regulation of numerous physiological processes.
[0003] Probiotic compositions contain live microorganisms that, when administered in appropriate amounts, provide beneficial effects to the host. The mechanisms by which these beneficial effects are achieved include reduced intestinal permeability, increased mucin secretion by goblet cells, increased production of defensins that prevent pathogen colonization, increased production of short-chain fatty acids, stimulation of IgA secretion, reduced luminal pH, and increased tolerance of immune cells to commensal microorganisms while maintaining the ability to respond to pathogens (Gallo et al., "Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate", World J. Gastroenterol. 22:7186-7202 (2016); Barko et al., "The gastrointestinal microbiome: a review", J. Vet. Internal Med. 32:9-25 (2018)). It is also believed that non-live microorganisms can impart beneficial effects by attaching to the mucus layer of the gastrointestinal (GI) tract and stimulating immune function (Barko et al., 2018).
[0004] Probiotic compositions benefit their hosts by supporting the proliferation of beneficial intestinal microflora. Probiotics are able to produce beneficial effects on their hosts without permanently altering the microbiome, perhaps due to transient colonization in the intestine (Ceapa et al., "Influence of fermented mild products, prebiotics and probiotics on microbiota composition and health", Best Pract. Res. Clin. Gastroenterol. 27: 139-155 (2013); Barko et al., 2018).
[0005] In addition, probiotics can modulate the frequency of tight junction proteins that act as barriers in the paracellular pathway of intestinal cells. By enhancing intestinal barrier function, probiotics act as preventive agents to resist the adverse effects of pathogens, thereby promoting positive effects on digestive and immune health. In addition, it seems that the beneficial effects of probiotics can be strain-specific, and most probiotic studies have investigated Bifidobacterium and Lactobacillus strains in different special groups (i.e., diabetes, obesity) in the general population.
[0006] Some believe that members of the genus Bacillus have higher probiotic potential than lactic acid-producing bacteria because they have a high level of viability in the GI tract and are able to multiply and increase in number, even in the adverse environmental conditions of low pH. However, other researchers believe that bacteria do not have to be alive to exert a probiotic effect (Biourge et al., "The use of probiotics in the diet of dogs", J. Nutrition, 128(12th Supplement): 2730S-2732S (1998); Schmitz and Suchodolski, "Understanding the canine intestinal microbiota and its modification by pro-, pre-, and synbiotics-what is the evidence? " Vet. Med. Sci., 2: 71-94 (2016)).
[0007] Currently, probiotics are considered to be a potential alternative treatment for dogs with intestinal disorders such as leaky gut. Endotoxemia is a condition that exists in all mammals. It is characterized by elevated serum endotoxin levels. It can affect GI permeability, GI microbiota, or both (McFarlin et al., 2015). In human medicine, this increase is known to occur about 5 hours after a meal, and it affects about 33% of the population (Kirshnan, "Metabolic endotoxemia, A driving force behind chronic illness [metabolic endotoxemia, the driving force behind chronic illness]", Aapi's nutrition guide to optimal health using principles of functional medicine & nutritional genomics [Aapi's best health nutrition guide, using functional medicine and nutritional genomics principles], Part III: 269-286 (2017)). In the case of dogs, mild levels of endotoxemia have been reported following intravenous infusion of low-dose endotoxin (Bartko et al., “Selective glucocorticoid receptor modulation inhibits cytokiner responses in a canine model of mild endotoxemia,” Pharmacolog. Res. 125:215-223 (2017); Devries et al., “Establishment of a Low Dose Canine Endotoxemia Model to Test Anti-Inflammatory Drugs: Effects of Prednisolone,” Intl. J. Immunopathol. and Pharmacol. [International Journal of Immunopathology and Pharmacology], 26(4):861-869 (2013)), but naturally occurring endotoxemia has not been characterized.Experimentally induced endotoxemia has been studied in humans using a bolus injection of Escherichia coli endotoxin (Deventer et al., "Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways", Blood, 76(12):2520-2526 (1990)) or by ingestion of a high-fat meal (McFarlin et al., "Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers", World Health Organization, 2003). J. Gastrointest. Pathophysiol. [World Journal of Gastrointestinal Pathophysiology], 8: 117-126 (2017)). Summary of the invention
[0008] In one embodiment, the present invention relates to a method of reducing endotoxemia in a dog, the method comprising the steps of providing a probiotic composition comprising Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici, and administering the probiotic composition to the dog in an amount effective to reduce endotoxemia in the dog. In one embodiment, the present invention also relates to improving digestion and digestive processes in a dog, and / or treating a digestive disorder in a dog.
[0009] In one embodiment, the present invention includes Bacillus subtilis HU58 and / or Bacillus licheniformis SL-307. In one embodiment, the total CFU of a discrete dosage unit of the probiotic composition can be about 1 billion to about 10 billion CFU, including, for example, about 2.5 billion to about 4 billion CFU. In one embodiment, the method of the present invention can be used permanently or temporarily in healthy dogs or in dogs with gastrointestinal disorders. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 is a combined diagram showing the inclusion and treatment of subjects according to the present invention.
[0011] Figure 2 is a graph showing the average digestibility parameters of dry matter, crude protein, crude fat, crude cellulose and NFE in healthy dogs before and after administration of a probiotic composition of the present invention.
[0012] Figure 3 is a graph showing mean values and trend lines related to endotoxemia in healthy dogs before and after administration of a probiotic composition according to the present invention.
[0013] Figure 4 is a graph showing mean CD14 values in healthy dogs before and after administration of a probiotic composition of the present invention.
[0014] Figure 5 is a graph showing mean IL-1B values in healthy dogs before and after administration of a probiotic composition of the present invention.
[0015] Figure 6 is a graph showing mean values and trend lines for endotoxemia in dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0016] Figure 7 is a graph showing mean CD14 values in dogs suffering from dysbiosis before and after administration of a probiotic composition of the present invention.
[0017] Figure 8 is a graph showing mean IL-1B values in dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0018] Fig. 9 is a graph showing the hematocrit kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0019] Fig.10 is a graph showing hemoglobin kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0020] Fig.11 is a graph showing red blood cell dynamics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0021] Fig.12 is a graph showing the mean corpuscular volume kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the invention.
[0022] Fig.13 is a graph showing mean corpuscular hemoglobin kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0023] Fig.14 is a graph showing the kinetics of mean corpuscular hemoglobin concentration in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0024] Fig.15 is a graph showing leukocyte dynamics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0025] Fig.16 is a graph showing neutrophil kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0026] Fig.17 is a graph showing eosinophil kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0027] Fig.18 is a graph showing monocyte kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0028] Fig.19 is a graph showing lymphocyte kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0029] Fig. 20 is a graph showing the kinetics of alanine aminotransferase in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0030] Fig.21 is a graph showing albumin kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0031] Fig. 22 is a graph showing the kinetics of alkaline phosphatase in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0032] Fig.23 is a graph showing amylase kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0033] Fig.24 is a graph showing creatinine kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0034] Fig.25is a graph showing globulin kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0035] Fig.26 is a graph showing glucose kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0036] Fig. 27 is a graph showing total bilirubin kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0037] Fig.28 is a graph showing total protein kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0038] Fig.29 is a graph showing blood urea nitrogen kinetics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0039] Fig.30 is a graph showing blood calcium dynamics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0040] Fig.31 is a graph showing phosphorus dynamics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0041] Fig.32 is a graph showing potassium dynamics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0042] Fig.33 is a graph showing sodium dynamics in healthy dogs and dogs with dysbiosis before and after administration of a probiotic composition of the present invention.
[0043] Fig.34 is a graph showing the changes in endotoxemia levels (EU / ml) in healthy dogs and dogs with dysbiosis before (day 0) and after (day 31) administration of a probiotic composition of the present invention.
[0044] Fig.35 is a graph showing the percent reduction in endotoxin levels before / ante- and after / post- from day 0 to day 31 in healthy dogs and dogs with dysbiosis according to the present invention. DETAILED DESCRIPTION
[0045] The present invention relates to a method of administering a probiotic composition to a dog, the probiotic composition comprising Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici.
[0046] The following definitions and discussions are intended to guide understanding but are not intended to be limiting with respect to other disclosures of the present application. References to percentages (%) in the compositions of the present invention are % by weight of a given component relative to the total weight of the composition in question, also expressed as "w / w", unless otherwise indicated.
[0047] As used herein, the verb "comprise" and its variations used in this specification and claims are used in their non-restrictive sense, meaning including the items following the word, but not excluding items not specifically mentioned. In addition, the indefinite article "a or an" referring to an element does not exclude the possibility that more than one element is present, unless the context clearly requires the presence of one and only one element. Therefore, the indefinite article "a or an" usually means "at least one".
[0048] As used herein, "effective amount" or "amount effective for..." is defined as an amount that is effective to achieve the desired biological result (e.g., reduce, prevent or treat a disease or condition and / or induce a specific beneficial effect) at the necessary dosage and time period. The effective amount of the composition of the present disclosure may vary according to factors such as the age, sex and weight of the individual. The dosage regimen may be adjusted to provide the best response. Several separate doses may be administered daily, or the dose may be proportionally reduced as indicated by the urgency of the individual's situation. According to the present invention, a single daily dose may be administered according to an effective amount of Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici. As will be readily understood, the composition according to the present disclosure may be administered in a single portion or multiple portions spaced throughout the day. As will be understood by those skilled in the art, the serving size is not necessarily limited to daily administration, and may be administered every two days or every three days or in other convenient and effective ways. Depending on the urgency of the situation, administration on a given day may be in a single portion or multiple portions spaced throughout the day.
[0049] According to the present invention, a "subject," "patient" or other individual according to the present invention is a dog.
[0050] The "probiotic composition" of the present invention comprises Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici. The probiotic composition of the present invention may comprise, consist essentially of, or consist of: Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici. In one embodiment, the probiotic composition of the present invention is An encapsulated dietary supplement containing a total of 4 billion CFU of Bacillus subtilis HU58, Bacillus licheniformis SL-307 and Pediococcus acidilactici and 180 mg of defatted grass-fed beef liver extract per capsule. HU58 ("ProBioteneTM ”) is a strain of Bacillus subtilis, and its preparation is manufactured by Viridis BioPharma Pvt. Ltd. in Mumbai, India. Bacillus subtilis HU58 has been deposited at the National Center for Biotechnology Research in the United States under the accession number EF101709. The Bacillus Genetic Stock Center (“BGSC”) has assigned the number 3A34 to Bacillus HU58, while the strain number assigned by NCIMB Ltd. is 30283. Bacillus licheniformis strains are also used in the probiotic composition of the present invention. Pediococcus acidilactici strains are also used in the probiotic composition of the present invention. In one embodiment, the probiotic composition of the present invention comprises about 2 billion CFU HU58, about 500 million to 1 billion CFU Pediococcus acidilactici, and 100 million CFU Bacillus licheniformis, and is administered orally in a capsule once a day; in one embodiment, such a composition is In one embodiment, the capsules of the present invention are made of cellulose. In various embodiments, the present disclosure discloses probiotic compositions and methods of producing and using these probiotic compositions. In other embodiments, the probiotic compositions of the present invention support digestive health in dogs, reduce endotoxemia in dogs, and / or treat digestive disorders in dogs.
[0051] These effects have been experimentally demonstrated based on supplementing study participants with a composition comprising one or more strains of colonizing probiotic material, which may be spore-based probiotic bacterial strains.
[0052] The probiotic compositions of the present invention may be measured in colony forming units ("CFU"). Effective doses are typically hundreds of millions of CFU or higher. If the probiotics are used to aid digestion, the probiotics should be taken with meals, otherwise the probiotics may survive if taken between meals, especially if taken with a liquid that helps dilute stomach acid and allow the probiotics to enter the digestive tract more quickly. Probiotics may be administered short-term or long-term.
[0053] In some embodiments, the concentration of the probiotic microorganisms in the composition may be at least about 1.10 9 CFU / g, at least about 2·10 9 CFU / g, at least about 3.10 9 CFU / g, at least about 4·10 9 CFU / g, at least about 5·10 9 CFU / g, at least about 6.10 9 CFU / g, at least about 7.10 9CFU / g, at least about 8.10 9 CFU / g, at least about 9.10 9 CFU / g, at least about 1·10 10 CFU / g, at least about 2·10 10 CFU / g, at least about 3.10 10 CFU / g, at least about 4·10 10 CFU / g, at least about 5·10 10 CFU / g, at least about 6.10 10 CFU / g, at least about 7.10 10 CFU / g, at least about 8.10 10 CFU / g, at least about 9.10 10 CFU / g, or at least about 1·10 11 CFU / g, and any range therein.
[0054] In one embodiment, the spore-based probiotic composition may include spores having a survival rate after in situ exposure to gastric acid in any range of about 75% to about 99%, about 80% to about 95%, about 85% to about 90%, and greater than about 90%. The spore-based probiotic composition may include a number of spores in any range of about 1 billion to about 10 billion spores, about 1.5 billion spores to about 9.5 billion spores, about 2.5 billion spores to about 8 billion spores, about 3 billion spores to about 7 billion spores, about 3.5 billion spores to about 6 billion spores, about 4 billion spores to about 5 billion spores, and about 4 billion spores.
[0055] In one embodiment, the spore-based probiotic composition may include a liquid, confectionery, powder or pill form, or may be added to a food product or formulated as a dietary supplement. For example, in one embodiment, the probiotic composition may be in powder form and added to dog food. In one embodiment, there are about 1.10 10 CFU microorganisms, wherein each gram contains about 60% or less of the bacterial mass and about 40% of the carrier system. In other embodiments, each gram contains about 70% or less of the bacterial mass and about 30% of the carrier system, about 80% or less of the bacterial mass and about 20% of the carrier system, about 90% or less of the bacterial mass and about 10% of the carrier system, about 50% or less of the bacterial mass and about 50% of the carrier system, about 40% or less of the bacterial mass and about 60% of the carrier system, about 30% or less of the bacterial mass and about 70% of the carrier system, about 20% or less of the bacterial mass and about 80% of the carrier system, or about 10% or less of the bacterial mass and about 90% of the carrier system.
[0056] Embodiments of the methods and compositions disclosed herein may include spore-based probiotics. Spore-based probiotics are composed of endosomes that are highly tolerant to acidic pH, are stable at room temperature, and deliver larger quantities of highly viable bacteria to the small intestine than traditional probiotic supplements. Traditional microencapsulation uses live microorganisms that are then microencapsulated in an effort to protect them; however, this is a process that inherently results in the eventual death of the microorganism, thereby reducing the efficacy of the microorganism. The use of spore-based microorganisms that are naturally microencapsulated to form endosomes may be preferred because these microorganisms are dormant and do not experience a decrease in efficacy over time.
[0057] These spore-based microorganisms are also particularly heat stable and can withstand UV pasteurization, so they can also be added to food products or beverages prior to heat exposure or UV pasteurization without experiencing a decrease in efficacy over time.
[0058] Microencapsulation
[0059] In certain embodiments, the probiotic microorganisms are microencapsulated before being added to the probiotic composition. Microencapsulation is a process of surrounding tiny particles or droplets with a coating to obtain small capsules with many useful properties. In a relatively simple form, microcapsules are small spheres with uniform walls around them. The material inside the microcapsule is called the core, internal phase or filler, while the wall is sometimes called a shell, coating or membrane. The diameter of most microcapsules is between a few microns and a few millimeters.
[0060] The definition of "microencapsulation" has been expanded and includes most foods. Every type of food ingredient has been encapsulated; spices are the most common. The microencapsulation technology depends on the physical and chemical properties of the material to be encapsulated. See, for example, LS Jackson and K. Lee, Microencapsulation and the food industry, LEBENSMITTEL-WISSENSCHAFT TECHNOLOGIE (January 1, 1991), which is incorporated herein by reference for the purpose of describing microencapsulation.
[0061] However, many microcapsules have little resemblance to these simple spheres. The core can be a crystal, a jagged adsorbent particle, an emulsion, a Pickering emulsion, a solid suspension, or a suspension of smaller microcapsules. The microcapsules can even have multiple walls. Various techniques can be used to produce microcapsules, and those of ordinary skill in the art will understand each of the various such techniques. These techniques that can be used to produce microcapsules include, but are not limited to, pan coating, air suspension coating, centrifugal extrusion, vibrating nozzles, spray drying, ionic gelation, interfacial polycondensation, interfacial crosslinking, in-situ polymerization, and matrix polymerization as described below.
[0062] Pan coating
[0063] The pan coating process, widely used in the pharmaceutical industry, is one of the oldest industrial procedures for forming small coated granules or tablets. The granules are tumbled in a pan or other device while the coating material is slowly applied.
[0064] Air suspension coating
[0065] Air suspension coating was first described in 1959 by Professor Dale EavinWurster of the University of Wisconsin and offers improved control and flexibility compared to pan coating. In this process, solid particulate core materials are dispersed into a supporting airflow and coated with a polymer in a volatile solvent, leaving a very thin polymer layer on them. This process is repeated hundreds of times until the desired parameters (such as coating thickness, etc.) are obtained. The airflow supporting the particles also helps to dry them, and the drying rate is proportional to the airflow temperature, which can be changed to further affect the properties of the coating.
[0066] The recirculation of particles in the coating zone section is influenced by the chamber design and its operating parameters. The coating chamber is arranged so that the particles pass upward through the coating zone, then disperse into the slower moving air and sink back to the bottom of the coating chamber, repeatedly passing through the coating zone until the desired coating thickness is achieved.
[0067] Centrifugal Extrusion
[0068] A rotating extrusion head containing a concentric nozzle is used to encapsulate the liquid. In this process, a core liquid jet is surrounded by a shell of a wall solution or melt. As the jet moves through the air, due to Rayleigh instability, the jet breaks into core droplets, each of which is coated with a wall solution. While the droplets are in flight, the molten wall may harden or the solvent may evaporate from the wall solution. Since most droplets are within +10% of the average diameter, they fall in a narrow ring around the spray nozzle. Therefore, if necessary, the capsules can be hardened after formation by capturing them in an annular hardening bath. This process is very suitable for forming particles with a diameter of 400-2,000 μm. Since the droplets are formed by the breakup of a liquid jet, the process is only applicable to liquids or slurries. High productivity can be achieved, i.e., up to 22.5 kg (50 lb) of microcapsules can be produced per head per hour per nozzle. Heads containing 16 nozzles are available.
[0069] Vibrating nozzle
[0070] Core-shell encapsulation or micronization (matrix encapsulation) can be performed using laminar flow through the nozzle and additional vibration of the nozzle or the liquid. The vibration must be performed in resonance with the Rayleigh instability and produce very uniform droplets. The liquid can consist of any liquid with a defined viscosity (0-10,000 mPa·s has been proven to be effective), such as solutions, emulsions, suspensions, melts, etc. Solidification can be performed using internal gelation (e.g. sol-gel processing, melting) or external gelation (additional binder system, for example, in a slurry), depending on the gelation system used. The process is very suitable for producing droplets between 20-10,000 μm, and applications for smaller and larger droplets are known. These devices are mainly used in industry and research with a capacity of 1-20,000 kg / hour (2-44,000 lb / h) at operating temperatures of 20°C-1500°C (68°F-2732°F) (room temperature up to molten silicon). Nozzle heads with one up to several hundred thousand nozzles are available.
[0071] Spray drying
[0072] Spray drying is used as a microencapsulation technique when the active material is dissolved or suspended in a melt or polymer solution and is trapped in the dry particles. The main advantage is the ability to process unstable materials due to the short contact time in the dryer; moreover, the operation is economical. In modern spray dryers, the viscosity of the solution to be sprayed can be up to 300 mPa·s. By combining this technique with the use of supercritical carbon dioxide, sensitive materials such as proteins can be encapsulated.
[0073] Ionic gelation
[0074] The coacervation-phase separation process consists of three steps carried out under continuous stirring:
[0075] (1) Formation of three immiscible chemical phases: liquid manufacturing vehicle phase, core material phase and coating material phase.
[0076] (2) Deposition of coating: The core material is dispersed in the coating polymer solution. The coating polymer material is coated around the core. The liquid polymer coating is deposited around the core by the polymer adsorbed at the interface formed between the core material and the vehicle phase.
[0077] (3) Hardening of the coating: The coating material is immiscible in the vehicle phase and its form hardens. Hardening techniques include heat, cross-linking or dissolvation.
[0078] Interfacial polycondensation
[0079] In interfacial polycondensation, the two reactants in the polycondensation meet at the interface and react rapidly. The basis of the process is the classical Schotten-Baumann reaction between acid chlorides and compounds containing active hydrogen atoms, such as amines or alcohols, polyesters, polyureas or polyurethanes. Under suitable conditions, a flexible thin wall forms rapidly at the interface. A solution of pesticide and diacyl chloride is emulsified in water, and an aqueous solution containing amine and polyfunctional isocyanate is added. A base is present to neutralize the acid formed during the reaction. The condensed polymer wall forms instantaneously at the interface of the emulsion droplets.
[0080] Interface cross-linking
[0081] Interfacial crosslinking originates from interfacial polycondensation and was developed to avoid the use of toxic diamines for pharmaceutical or cosmetic applications. In this method, small bifunctional monomers containing active hydrogen atoms are replaced by polymers of biological origin, such as proteins. When the reaction is carried out at the emulsion interface, the acyl chloride reacts with various functional groups of the protein, thereby forming a membrane. This method is very versatile and the properties of the microcapsules (size, porosity, degradability, mechanical resistance) can be varied. The flow of artificial microcapsules in microfluorine channels is envisioned.
[0082] In-situ polymerization
[0083] In some microencapsulation processes, direct polymerization of a single monomer is carried out on the particle surface. In one process, for example, cellulose fibers are encapsulated in polyethylene while immersed in anhydrous toluene. A typical deposition rate is about 0.5 μm / min. The coating thickness ranges from 0.2-75 μm (0.0079-3.0 mils). The coating is uniform, even on sharp protrusions. Protein microcapsules are biocompatible and biodegradable, and the presence of the protein backbone makes the membranes more resistant and elastic than those obtained by interfacial polycondensation.
[0084] Matrix polymerization
[0085] In many processes, the core material is embedded in a polymer matrix during particle formation. A simple process of this type is spray drying, in which the particles are formed by evaporating the solvent from the matrix material. However, solidification of the matrix can also be caused by chemical changes.
[0086] In one embodiment, "administering" refers to providing the probiotic composition of the present invention to a subject, so that Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici can reach the gastrointestinal tract of the subject, and act on the tissues and / or cells of the GI tract and / or in the GI tract (such as bacteria) directly and / or, for example, by producing and releasing metabolites or other active chemicals, thereby reducing endotoxemia, improving the digestive process and / or treating gastrointestinal disorders. In one embodiment, the subject is a healthy dog or a dog with a GI tract disorder. According to the present invention, administration to a subject can be oral, for example, in the form of a dietary supplement, in a solid dosage form (such as a capsule) or in a liquid dosage form and / or via other routes (for example, as a suppository through the rectum). In one embodiment, the probiotic composition of the present invention (such as ) is taken orally before, with or after a meal. "Simultaneous administration" means that the probiotics of the present invention are administered simultaneously (including on the same day) with, for example, antibiotics or other substances that may be detrimental to intestinal health, or with, for example, another substance that is beneficial to intestinal health.
[0087] In one embodiment, a "dietary supplement" according to the present invention refers to a probiotic composition of the present invention that is orally administered as a supplement to a subject's diet, rather than as a natural or conventional food. In one embodiment, the dietary supplement comprises an effective amount of Bacillus subtilis, Bacillus licheniformis, and Pediococcus acidilactici, such that these substances enter the dog's digestive tract when administered to the dog and function appropriately in the dog's digestive tract and elsewhere in the body, thereby reducing endotoxemia, improving the digestive process, and / or treating gastrointestinal disorders.
[0088] In one embodiment, the dietary supplement or other form of the probiotic composition of the present invention is administered daily for 1 day, 1-7 days, 1-14 days, 1-30 days, 1-31 days, 1-32 days, 1-60 days, or for another period of time. In one embodiment, the probiotic composition can be taken long-term, such as daily or weekly, for several months or a year or years.
[0089] In one embodiment, the probiotic composition of the present invention may be administered to treat intestinal dysbiosis, endotoxemia, or other disorders of the GI tract in a subject.
[0090] In one embodiment, the probiotic composition of the present invention may be administered to prevent intestinal dysbiosis, endotoxemia, or other disorders of the GI tract in a subject.
[0091] In one embodiment, the probiotic composition of the present invention may be administered to improve the health and digestion of a subject's GI tract.
[0092] The present invention can be further understood in conjunction with the following examples and embodiments. The examples and embodiments described throughout this application are provided for the purpose of illustrating the present invention and are not intended to be limiting.
[0093] Examples
[0094] In this example, a spore-based probiotic composition according to the present invention (containing Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici) reduced endotoxemia in dogs after 30 days of administration. In addition, a pattern of natural postprandial endotoxemia levels in clinically healthy dogs and those with significant dysbiosis was identified.
[0095] Study Design
[0096] A total of 18 adult dogs between the ages of 4 months and 7 years were enrolled in the study.A probiotic composition comprising Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici was administered to the dogs once daily with meals for 30 days (see Table 1).
[0097] On day -5 to day 0, feces were collected from healthy dogs.
[0098] On day 0 of the study, the dogs were clinically examined and feces and blood samples were collected. To detect endotoxemia, blood samples were collected before and after meals (6 hours and 12 hours). A clinical examination was performed by a veterinarian to assess the general health of each dog. The examination included collecting body temperature, heart rate, and respiratory rate data.
[0099] On days 1 to 30, the probiotic composition was administered to the animals according to the manufacturer's recommendations. On day 31, all dogs were clinically examined as described above, and biological samples (feces and blood) were collected for paraclinical examinations. To detect endotoxemia, pre-prandial and post-prandial (6 hours and 12 hours) blood samples were collected.
[0100] Feces collected from healthy dogs were used at least for digestibility studies on days 31 to 36.
[0101] Table 1
[0102] Research Timeline
[0103]
[0104] Study Group
[0105] This study used real-world clinical cases, such as Figure 1 as shown in . Figure 1 Patient disposition is shown. Patients were carefully screened using the study exclusion / inclusion criteria described below. Eligible dogs were enrolled in the study. Of the 18 dogs enrolled in the study, a total of 11 dogs completed the entire study period: 5 (five) healthy dogs (Table 2) and 6 (six) dogs with dysbiosis (Table 3). The dogs did not undergo any lifestyle or nutritional changes throughout the study.
[0106] Inclusion criteria for healthy dogs included the absence of GI manifestations (diarrhea, vomiting), no history of antibiotic treatment in the past 6 months, clinically healthy and eating 1 normal meal per day. Dogs were excluded from the group of healthy dogs if they had acute liver or kidney disease, intestinal parasites, or had been treated with antibiotics in the past 6 months.
[0107] For dogs with intestinal dysbiosis, inclusion criteria were current antibiotic treatment (minimum duration of 2 weeks), or the presence of GI manifestations (diarrhea, vomiting), and eating one normal meal per day. Dogs were excluded if they had acute liver or kidney disease or if they had intestinal parasites.
[0108] Table 2
[0109] Healthy Dog
[0110]
[0111] *Terminated early; already receiving probiotics; remaining in study for stool scoring and digestibility studies only
[0112] Table 3
[0113] Dogs with intestinal dysbiosis
[0114]
[0115] treat
[0116] The probiotic products tested contained two bacterial strains: Bacillus subtilis HU58 and Pediococcus acidilactici (FidoSpore TM ). The probiotics were given in capsule form. One capsule was administered daily for 30 days along with the daily diet. Liver powder was used to improve the taste of the probiotic product and ensure that it was ingested.
[0117] Clinical investigation
[0118] To assess the health status of the dogs entering the study and to obtain baseline clinical data, each dog was given a clinical assessment. A general clinical examination was performed on the dogs, including the collection of data related to clinical parameters. In this study, the normal range values for dogs in the Merck Veterinary Manual (Merck Veterinary Manual) (2016) were considered normal clinical values.
[0119] Fecal scoring
[0120] During probiotic treatment, owners were asked to complete the Optidigest clinical form developed by Purina ( www.purina.com ; The original table can be found at https: / / www.purina.ro / produse / proplan- optidigest The clinical scale is divided into three parts: stool consistency, stool volume and odor, and gutrambling and flatulence.
[0121] The stool consistency section assessed the dogs' stool throughout the day using a stool scoring scale. The scale is described as follows: 1 - very hard and dry, 2 - firm but not hard, 3 - log-like, 4 - very moist, 5 - very moist but with a distinct shape, 6 - with texture but no defined shape, 7 - watery with no texture, flat.
[0122] The amount and odor of stool were also recorded throughout the day. The amount of stool was graded as 1-small amount, 2-normal amount, 3-large amount, 4-very large amount. The odor was recorded as 1-very little odor, 2-low odor, 3-moderately bad odor, 4-bad odor, 5-very bad odor.
[0123] Intestinal disturbances and bloating were assessed during the day and their presence or absence was recorded.
[0124] Fill out all of this data on Days 1, 7, 15, and 30 of the study.
[0125] Digestibility
[0126] The digestibility of a feed is measured using the digestibility coefficient (DC), which represents the portion of the feed or feed nutrients that is not recovered in the feces, i.e., the portion that has been absorbed by the animal. Equation I is used to determine the apparent digestibility coefficient (ADC%):
[0127]
[0128] Based on this principle, the levels of the following items were determined: dry matter (DM), crude protein - Kjeldahl method (CP), crude fat - Soxhlet method (CF), crude cellulose - Weende method (CC), nitrogen-free extract (NFE).
[0129] Digestibility was determined only in healthy dogs. Biological samples were feces and food samples. Feces were collected 5 days before the start of treatment and 5 days after the end of the administration of the probiotic composition.
[0130] Clinical Assisted Investigation
[0131] Parasitology
[0132] The 11 dogs included in the study were subjected to fecal examinations before and after the administration of probiotics. Both flotation (Willis method) and sedimentation techniques were used. The aim was to see if the effect of the probiotics was not misinterpreted by the presence of internal parasites.
[0133] Hematological parameters
[0134] Blood was collected into blood tubes with anticoagulant (EDTA). Hematological samples were analyzed by the device ABACUS JUNIOR VET (Table 4). All data obtained were compared with references from the Merck Veterinary Manual (2016).
[0135] These assessments were performed before (Day 0) and after (Day 31) administration of the probiotic composition (Table 5).
[0136] Table 4
[0137] Hematological parameters and their methods
[0138]
[0139] Table 5
[0140] Blood sample investigation (healthy dogs and dogs with dysbiosis)
[0141]
[0142] *For 3 dogs only
[0143] Biochemical parameters
[0144] The Vet Scan chemistry analyzer is used with a comprehensive test that provides quantitative determination of alanine aminotransferase (ALT), albumin (ALB), alkaline phosphatase (ALP), amylase (AMY), total calcium (CA ++ ), creatinine (CRE), globulin (GLOB), glucose (GLU), phosphorus (PHOS), potassium (K+), sodium (NA+), total bilirubin (TBIL), total protein (TP), and urea nitrogen (BUN). All data obtained were compared with references from the Merck Veterinary Manual (2016).
[0145] These assessments were performed before (Day 0) and after (Day 31) administration of the probiotic composition (Table 5).
[0146] Determination of endotoxemia
[0147] To measure endotoxemia, we used the ToxinSensor TM Chromogenic LAL Endotoxin Assay Kit (GenScript, Piscataway, New Jersey (USA)). This method utilizes a modified horseshoe crab amebocyte lysate and a synthetic chromogenic substrate to detect endotoxins by color development. The end product can be measured using a spectrophotometer (545nm filter), and endotoxin levels can be determined by comparison with a standard curve. The kit has a minimum endotoxin detection limit of 0.01EU / mL and a measurable concentration range of 0.01 to 1EU / mL.
[0148] All dogs (healthy and dysbiosis) were evaluated for endotoxemia. The study protocol included daily endotoxemia assessments of serum before and after meals (6 hours and 12 hours) during probiotic administration (Table 5). Endotoxemia was assessed using the following sera: undiluted serum, 1:1 diluted serum, 1:2 diluted serum. These assessments were performed before (Day 0) and after (Day 31) administration of the probiotic composition (Table 5). The endotoxemia was assessed using the following sera: undiluted serum, 1:1 diluted serum, 1:2 diluted serum. These assessments were performed before (Day 0) and after (Day 31) administration of the probiotic composition (Table 5). The endotoxemia was assessed using the standard curve (R 2 =0.9808) The results were calculated for the 1:2 diluted serum.
[0149] Immune / inflammatory parameters
[0150] To investigate immune / inflammatory parameters we used:
[0151] Canine IL-1β (interleukin 1β) ELISA kit - according to the standard curve (R 2 =0.9527) calculation results.
[0152] Nori Canine CD14 ELISA Kit - According to the standard curve (R 2=0.991) calculation results.
[0153] Canine IL-6 (Interleukin 6) ELISA Kit - For this parameter, the OD value is not within the standard curve and the result cannot be interpreted.
[0154] All dogs (healthy and with dysbiosis) were evaluated for IL1B (interleukin-1-β, an important proinflammatory cytokine in the host defense response to infection and injury) and CD14 (a key molecule for activating innate immune cells). The investigation protocol was identical to that of endotoxemia. For dogs with dysbiosis, the investigation protocol included the evaluation of this parameter in pre- and post-prandial (6 and 12 hours) kinetics. These evaluations were performed before (day 0) and after (day 31) administration of the probiotic composition (Table 5).
[0155] For the group of healthy dogs, due to hemolysis of some blood samples and modifications of the protocol, we only have complete kinetics for the results before (day 0) and after (day 31) administration of the probiotic composition, but not for the pre- and 6 or 12 h post-meal results on these days (Table 5).
[0156] Statistical analysis
[0157] Data were analyzed using conditional analysis of variance (ANOVA) with the following conditions (Equation II):
[0158] (Healthy dogs or dogs with dysbiosis) × (Experimental time (Day 0 and Day 31)) × (Meal time (before meal, 6 hours after meal, 12 hours after meal)).
[0159] Equation II
[0160] Significance was set at p < 0.05 and determined using the Student-Newman-Keuls multiple comparison test. 2 The variation of the study parameters was determined using linear regression.
[0161] result
[0162] Clinical examination
[0163] A gross clinical examination was performed on all dogs studied before starting probiotic treatment (Day 0) and at the end of the study (Day 31).
[0164] During the clinical examination, none of the dogs had significant medical needs. All dogs studied had normal body temperature, ranging from 37.9°C to 39.9°C. Heart rate did not indicate any problems of significant clinical importance. All dogs studied had a respiratory rate higher than normal. The normal resting value of the respiratory rate for a dog is 18 to 34 breaths per minute. An elevated respiratory rate is not alarming and can be interpreted as excitement, stress, and / or high temperature in the examination room.
[0165] Treatment with the probiotic composition of the present invention did not alter the clinical manifestations of healthy dogs. No symptoms such as diarrhea or vomiting were observed in healthy dogs. Probiotic treatment improved the appearance of the dogs' coat and induced improvement of skin lesions.
[0166] For dogs with dysbiosis, initial clinical examination revealed diarrhea, vomiting and / or skin lesions; clinical symptoms varied depending on the symptoms of each eligible dog included in the study. After completing 30 days of treatment with the probiotic composition of the present invention, we observed a reduction in digestive symptoms, and in some cases, the digestive problems disappeared. Improvements were observed in the overall condition of these dogs, the details of which depended on the original diagnosis of each dog. In dog 10-Y (see Table 3), improvements in health status were observed upon completion of 30 days of treatment with the probiotic composition of the present invention, and the owner requested that treatment continue for an additional 30 days.
[0167] Fecal scoring
[0168] During treatment with the probiotic composition of the present invention, the dog owners were asked to complete the Optidigest clinical form developed by Purina, Inc. As discussed above, the clinical form is divided into three sections: stool consistency, stool volume and odor, and intestinal disturbances and bloating.
[0169] Treatment with the probiotic composition of the present invention slightly improved stool consistency and stool volume in most dogs. Treatment with the probiotic composition of the present invention did not improve stool odor according to the Optidigest table results. Intestinal disturbances were not present in any dog before, during, or after treatment with the probiotic composition of the present invention. However, bloating appeared to improve only in dogs that had bloating prior to treatment (see Table 6, Table 7).
[0170] Table 6
[0171] Healthy Dog Stool Scoring
[0172]
[0173] Table 7
[0174] Fecal Scoring of Dogs with Dysbiosis
[0175]
[0176] Digestibility
[0177] The digestibility of the feeds was studied by measuring the apparent digestibility coefficients, showing important improvements in the digestibility of all components studied (dry matter, crude fat, crude fiber and NFE), except for crude protein, where in one case (dog 02-H) the median value was reduced (see Table 8, Figure 2 For dry matter, crude protein and NFE, the improvement in digestibility was statistically significant (p<0.001).
[0178] Table 8
[0179] Evolution of digestibility (%) - healthy dogs
[0180]
[0181] *** p<0.001-extremely significant
[0182] hematology
[0183] The hematological parameters of the dogs were quite variable but were always within normal values for dogs. However, we observed slight increases in hemoglobin (Hb), mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) (see Tables 9 and 10).
[0184] Leukocyte values before and after treatment with the probiotic composition of the present invention showed variable results, but were still within the normal range for dogs. Eosinophil values tended to increase slightly in most dogs after treatment. Neutrophils, basophils, monocytes, and lymphocytes increased or decreased depending on the individual dog (see Tables 11 and 12). Individual and average variations were not considered to have pathological connotations.
[0185] A specific situation was observed in dogs with dysbiosis, where there was a small trend towards an increase in the mean eosinophil value. This was shown in a 14-M patient with eosinophilia (30%) after administration. This value correlates with the diagnosis of hookworm disease, which was not demonstrated before administration due to the biological cycle of the parasite (Ancylostoma coninum).
[0186] Table 9
[0187] Evolution of red blood cell parameters - healthy dog
[0188]
[0189] Table 10
[0190] Evolution of red blood cell parameters - dogs with dysbiosis
[0191]
[0192] Table 11
[0193] Evolution of leukocyte parameters - healthy dog
[0194]
[0195] Table 12
[0196] Evolution of leukocyte parameters - dogs with dysbiosis
[0197]
[0198] Biochemistry
[0199] Investigation of biochemical parameters indicated the health of different systems and organs and also indicated how the probiotic composition was acting on the dogs (Table 13).
[0200] Table 13
[0201] Biochemical parameters investigated
[0202]
[0203] Tables 14, 15, 16 and 17 present the results of biochemical parameters for all cases before and after treatment with the probiotic composition of the invention.
[0204] Biochemical parameters of the dogs were variable but were consistently within normal values for dogs. Biochemical results were correlated with clinical observations recorded before and after administration.
[0205] Patient 07-I showed high levels of ALT and potassium before administration in the group of healthy dogs. This increase was not associated with changes in other biochemical, hematological or clinical parameters, so the dog remained in the study. ALT levels after administration were within the physiological limits of the species, and potassium continued to be present at higher levels.
[0206] Table 14
[0207] Evolution of biochemical parameters - healthy dog
[0208]
[0209] Table 15
[0210] Evolution of biochemical parameters - Dogs with dysbiosis
[0211]
[0212] Table 16
[0213] Evolution of the ionogram - Healthy dog
[0214]
[0215] Table 17
[0216] Evolution of the ionogram - Dogs with dysbiosis
[0217]
[0218] endotoxemia
[0219] A. Healthy dog
[0220] It was observed that before administration of the probiotic composition, the average endotoxin level at 6 hours post-meal was elevated compared to the average level before the meal (pre-meal, 0.465 ± 0.113 EU / ml; 6 hours post-meal, 0.473 ± 0.172 EU / ml). After completing 30 days of probiotic administration, the same kinetics were observed, with endotoxin levels increasing from 0.3677 ± 0.2266 EU / ml (pre-meal) to 0.388 ± 0.233 EU / ml (6 hours post-meal) (see Table 19, showing changes in endotoxemia levels in healthy dogs and dogs with dysbiosis; and Fig.34 , shows the changes in endotoxemia levels (EU / ml) in healthy dogs and dogs with dysbiosis (before and after probiotic treatment). Due to the high level of variation between individual dogs, these differences were not statistically significant.
[0221] Importantly, after 30 days of administration of the probiotic composition, endotoxin levels decreased (see Tables 18 and Figure 3 ). Fig.35 The mean percentage decrease in endotoxin levels (EU / ml) from day 0 to day 31 in healthy dogs (before and after probiotic treatment) is shown and is as follows: pre-meal: 20.97%; 6 hours post-meal: 15%; 12 hours post-meal: 20.6%. Directly correlated with the trend of decreasing endotoxin levels is the evolution of CD14 (Table 20; Figure 4 The correlation coefficient of the two parameters (r=0.8452, R2=0.744) indicated statistical significance (p=0.05).
[0222] Table 18
[0223] Evolution of endotoxemia (FU / ml) - healthy dogs
[0224]
[0225] Table 19
[0226] Changes in endotoxemia levels (EU / ml)
[0227]
[0228] Table 20
[0229] Evolution of CD14 (pg / ml) - Healthy Dogs
[0230]
[0231] Regarding the evolution of IL1B levels, the value of this parameter remained relatively constant (Table 21, Figure 5 ).
[0232] Table 21
[0233] Evolution of IL1B (ng / ml) - Healthy Dogs
[0234]
[0235] B. Dogs with dysbiosis
[0236] After completing the treatment with the probiotic composition of the present invention, the endotoxemia level decreased (see Table 22, Figure 6 , Fig.34 The downward trend in endotoxemia observed after probiotic administration had a markedly increasing kinetics (R 2 =0.9536)( Figure 6 , Fig.34 ). This indicates a significant improvement in intestinal condition, which correlates with the clinical improvement seen in the dogs compared to their original diagnosis.
[0237] The most important change observed was the decrease in endotoxin levels in dogs with dysbiosis after completing 30 days of administration of the probiotic composition of the present invention ( Fig.35 The percentage decreases from day 0 to day 31 were as follows: before meal: 25.89%, 6 hours after meal: 35%, 12 hours after meal: 44.93%.
[0238] Table 22
[0239] Evolution of endotoxemia (EU / ml) - Dogs with dysbiosis
[0240]
[0241] Table 23
[0242] Evolution of CD14 (pg / ml) - Dogs with dysbiosis
[0243]
[0244] Table 24
[0245] Evolution of IL1B (ng / ml) - Dogs with dysbiosis
[0246]
[0247] From the perspective of CD14 evolution, the trend of reduced endotoxemia was directly related to the endotoxin level (Table 23, Figure 7 The correlation between the values before and after administration (before meal) was statistically significant (p=0.05), with correlation coefficients of r=0.08445 and R 2 =0.744. During the study period, IL1B levels remained relatively constant (Table 24, Figure 8 ).
[0248] Figure 9-33 The kinetics of hematological and biochemical parameters before and after administration in healthy dogs and dogs with dysbiosis are shown.
[0249] discuss
[0250] Endotoxemia is a condition that affects the normal functioning of the intestine. In veterinary medicine, metabolic endotoxemia has not been well studied. The currently available data are usually extrapolated from human medicine or obtained from studies using dogs as a canine model for product testing. From such studies, we have learned that small amounts of endotoxin (0.1g / kg) can produce mild endotoxemia in dogs (Bartko et al., 2017). Another study attempted to establish a canine endotoxemia model by intravenously injecting 0.03, 0.1 or 1.0ug / kg body weight lipopolysaccharide (which causes mild endotoxemia) in a single bolus (F. De Vries et al., 2013).
[0251] In humans, elevated endotoxin levels are known to occur approximately 5 hours after a meal (Kirshnan, 2017). Findings from human studies related to postprandial endotoxemia cannot be extrapolated to dogs because the digestive process (i.e., the enzymes used and the time required to complete food digestion) varies between individuals and breeds. In addition, the differences between dog and human diets are considerable, given that dogs are carnivores and humans are omnivores.
[0252] The type of diet fed to dogs has a major impact on the natural endotoxemia levels they experience. In our study, patient 01-K (a group of healthy dogs) followed a diet based on raw food, while the other four dogs in the group of healthy dogs only ate dry dog food. Because a sudden change in diet can cause GI imbalance, such as diarrhea or even vomiting, in our study, we did not change the diet of the dogs. The dogs selected for the study followed their usual diet, and the type of food and feeding interval were the same as they were used to. An in-depth study of the endotoxemia results showed that in the group of healthy dogs, there was a difference between the endotoxemia level of patient 01-K and other dogs. Although all five patients in the group of healthy dogs met the inclusion criteria of this study, in fact, patient 01-K followed a diet based on raw food, which may have an impact on the endotoxin level absorbed in the bloodstream after a meal.
[0253] Endotoxemia can be present in dogs without any clinical signs. In addition, it occurs in clinically healthy individuals after meals, regardless of the fat composition in the diet. In the healthy group, we observed that 6 hours after the meal, the average endotoxemia level rose (compared to the pre-meal level). Before starting probiotic treatment and after completing 30 days of probiotic treatment, this observation was indeed the case. Although we reported that after dogs completed probiotic treatment, in these dogs, the average endotoxin level rose (compared to the pre-meal) 6 hours after the meal, we also observed that before and after the completion of probiotic treatment, the endotoxin level detected significantly decreased. At the pre-meal and post-meal (6 hours and 12 hours) time point, this decline was observed. When comparing the endotoxin levels of the 0th day and the 31st day, the pre-meal level decreased by 20.97%, the level of 6 hours after the meal decreased by 15%, and the level of 12 hours after the meal decreased by 20.6%. These results support our following hypothesis that probiotic treatment can improve the intestinal digestion of healthy individuals, and thus reduce inflammation and endotoxemia levels.
[0254] The same pattern was observed in the group of dogs with dysbiosis. Endotoxemia levels were higher at all three time points (pre-meal, 6 hours post-meal, 12 hours post-meal) before starting probiotic treatment compared to those obtained after probiotic treatment was completed. In addition, the average percentage decrease was greater compared to the results in the healthy group. We report a 25.89% decrease in pre-meal endotoxin levels (day 0 to day 31), a 35% decrease 6 hours post-meal, and a 44.93% decrease 12 hours post-meal. This trend of decreased endotoxin levels after probiotic treatment suggests that probiotic treatment has efficacy and impact on re-establishing homeostasis in the GI tract.
[0255] Currently, there are no available data on the levels of postprandial natural endotoxemia in dogs. The main assumption of our study was extrapolated from human medicine (Kirshnan, 2017), where such data are available. However, the digestive process in dogs and humans is different. The amount of time that a partially digested food remains in the stomach of a dog is 4 hours to 8 hours, with slight variations between individuals and breeds, whereas for humans, the digestive process lasts about 1 hour. Another difference in the digestive process between the two species is the proportion of the GI tract length to the total body size of the individual (The Canine Digestion Process, Whole Dog Journal (2019), available at
[0256] https: / / www.whole-dog-journal.com / health / digestion / the-canine-digestion-process). Such aspects may affect the time when serum endotoxin can be detected. Taking this information into account, we decided to evaluate serum endotoxin levels 6 and 12 hours after the meal. In both groups of dogs, an increase in serum endotoxin levels was observed for all post-meal assessments (vs. pre-meal), with small variability. This finding supports our hypothesis that serum endotoxin levels increase after a meal.
[0257] Kinetic testing of serum endotoxin levels was performed with the goal of identifying the optimal time to measure postprandial endotoxin levels. After analyzing our results, we have determined that there is no optimal specific pattern or time point for measuring postprandial endotoxin levels. In all dogs studied, we observed an increase in postprandial endotoxin levels. This observation supports the hypothesis that after a meal, endotoxin levels increase, which has been demonstrated in humans (McFarlin et al., 2015; Kirshnan, 2017).
[0258] in conclusion
[0259] The data obtained in this study provide new information on the levels of natural endotoxemia in both healthy dogs and dogs with dysbiosis. In addition, for all canine patients enrolled in the study, administration of spore-based probiotics to the dogs reduced endotoxin levels before and after treatment and improved digestive processes.
[0260] Healthy Dog
[0261] In healthy dogs, the use of the probiotic composition of the present invention showed no adverse effects. It did not adversely affect the overall function of the dog's body. Hematological parameters and biochemical parameters showed slight changes before and after the application of the probiotic composition of the present invention, and the values were within the normal range. The application of the probiotic composition of the present invention improved the stool score and reduced flatulence. The stool weight dropped extensively after treatment, which was due to the improved digestibility of the feed. Studies on the digestibility of feed measured the apparent digestibility coefficient, showing important improvements in the digestibility of all studied components (dry matter, crude fat, crude cellulose and nitrogen-free extracts). Endotoxemia was analyzed before meals and 6 hours and 12 hours after meals. In some dogs, the postprandial endotoxemia values increased after 6 hours, while in other dogs, they increased after 12 hours. Overall, after 30 days of application of the probiotic composition of the present invention, a decrease in endotoxin levels was observed. On average, before meals, endotoxemia was reduced by 20.97% from day 0 to day 31. On average, endotoxemia decreased by 15% at 6 hours postprandial / post-meal from day 0 to day 31, and on average, endotoxemia decreased by 20.60% at 12 hours postprandial from day 0 to day 31. Directly associated with the trend of decreasing endotoxin levels was the evolution of CD14. The correlation coefficient of the two parameters (r = 0.8452; R 2 =0.744) indicated statistical significance (p=0.05). IL1B levels remained relatively constant.
[0262] Dogs with dysbiosis
[0263] In dogs with dysbiosis, we observed a reduction and / or disappearance of digestive disorders. An improvement in the overall condition of the dogs was observed, depending on the original diagnosis and pathology. Hematological and biochemical parameters showed variations depending on the pathology, with beneficial changes noted in the subjects. Endotoxemia decreased before and after administration, with the following mean percentage differences: 25.89% (pre-meal, days 0 to 31); 35%, 6 hours post-meal (days 0 to 31); and 44.93%, 12 hours post-meal (days 0 to 31). The downward trend in endotoxemia after administration included significantly increasing kinetics (R 2 =0.9536). The evolution of CD14 tended to decrease, which was directly related to the endotoxin level. The correlation between the values before and after the pre-meal administration was statistically significant (p=0.05). IL1B levels remained relatively constant during the study period.
[0264] Bioethics Committee Approval: This study was approved by the Bioethics Committee of the University of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca.
[0265] Study procedures were conducted after the owner of each participating dog was fully informed of all procedures involved and the products tested, and after all owners voluntarily signed an informed consent form regarding having their dogs participate. All study procedures were performed without harming any participating animal.
[0266] Unless otherwise specified herein or clearly contradicted by the context, in the context of describing the present invention (especially in the context of the claims), the use of the terms "a, an", "the", and similar indicators should be interpreted as including both the singular and the plural. Unless otherwise specified herein, the description of a range of values herein is intended only to be used as a shorthand method of referring to each individual value falling within the range one by one, and each individual value is incorporated into this specification as if it were described one by one herein. The use of the term "about" is intended to describe values that are above or below the stated value within a range of about ±10%; in other embodiments, the range values of these values may be above or below the stated value within a range of about ±5%; in other embodiments, the range values of these values may be above or below the stated value within a range of about ±2%; in other embodiments, the range values of these values may be above or below the stated value within a range of about ±1%. The foregoing ranges are intended to be clear from the context and no further limitations are implied. Unless otherwise specified herein or clearly contradicted by the context, all method steps described herein may be performed in any suitable order. Unless otherwise stated, the use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the present invention and is not intended to impose limitations on the scope of the present invention. The words in the specification should not be construed as indicating that any unclaimed element is essential to the practice of the present invention.
[0267] Although the present invention has been described in the foregoing specification with respect to certain embodiments of the invention and many details have been presented for the purpose of illustration, it will be apparent to those skilled in the art that the invention is susceptible of other embodiments and that certain details described herein may be modified considerably without departing from the basic principles of the invention.
[0268] The present invention may be embodied in other specific forms without departing from its spirit or essential attributes and, accordingly, reference should be made to the following claims rather than to the foregoing specification as indicating the scope of the invention.
Claims
1. Use of a probiotic composition consisting of Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici in the preparation of a veterinary medicament, dietary supplement, food product or food ingredient for use in a method for reducing endotoxemia in a dog, the method comprising administering the veterinary medicament, dietary supplement, food product or food ingredient to the dog in an amount effective to reduce endotoxemia in the dog, wherein the dog is a healthy dog or a dog suffering from dysbiosis; The Bacillus subtilis is Bacillus subtilis HU58, and the Bacillus licheniformis is Bacillus licheniformis SL-307.
2. The use according to claim 1, wherein the total number of Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici is 1 billion to 10 billion CFU.
3. The method of claim 2, wherein the total CFU is 2.5 billion to 5 billion CFU.
4. The use according to claim 2, wherein the total CFU is 2 billion CFU Bacillus subtilis HU58, 500 million to 1 billion CFU Pediococcus acidilactici and 100 million CFU Bacillus licheniformis.
5. The use of claim 1, wherein the probiotic composition is administered orally to the dog.
6. The use according to claim 5, wherein the oral administration continues for at least 30 days.
7. Use of a probiotic composition consisting of Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici in the preparation of a veterinary medicament, dietary supplement, food product or food ingredient for use in a method of improving digestion in the gastrointestinal tract of a dog, the method comprising administering the veterinary medicament, dietary supplement, food product or food ingredient to the dog in an amount effective to improve digestion in the gastrointestinal tract of the dog, wherein the dog is a healthy dog or a dog suffering from dysbiosis; The Bacillus subtilis is Bacillus subtilis HU58, and the Bacillus licheniformis is Bacillus licheniformis SL-307.
8. The use according to claim 7, wherein the total number of Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici is 1 billion to 10 billion CFU.
9. The method of claim 8, wherein the total CFU is 2.5 billion to 5 billion CFU.
10. The use according to claim 9, wherein the total CFU is 2 billion CFU Bacillus subtilis HU58, 500 million to 1 billion CFU Pediococcus acidilactici and 100 million CFU Bacillus licheniformis.
11. The use of claim 8, wherein the probiotic composition is administered orally to the dog.
12. The use according to claim 11, wherein the oral administration continues for at least 30 days.
13. Use of a probiotic composition consisting of Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici in the preparation of a veterinary medicament, dietary supplement, food product or food ingredient for use in a method for treating a digestive disorder in a dog, the method comprising administering the veterinary medicament, dietary supplement, food product or food ingredient to the dog in an amount effective to improve the digestive disorder in the dog, wherein the dog is a healthy dog or a dog suffering from dysbiosis; The Bacillus subtilis is Bacillus subtilis HU58, and the Bacillus licheniformis is Bacillus licheniformis SL-307.
14. The use according to claim 13, wherein the total number of Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici is 1 billion to 10 billion CFU.
15. The use of claim 14, wherein the total CFU is 2.5 billion to 5 billion CFU.
16. The use according to claim 14, wherein the total CFU is 2 billion CFU Bacillus subtilis HU58, 500 million to 1 billion CFU Pediococcus acidilactici and 100 million CFU Bacillus licheniformis.
17. The use of claim 13, wherein the probiotic composition is administered orally to the dog.
18. The use according to claim 17, wherein the oral administration continues for at least 30 days.
19. The use according to claims 1 to 18, wherein the veterinary medicament, dietary supplement, food product or food ingredient is in the form of a liquid, confectionery, beverage, powder, capsule or pill, or is added to a food product or formulated as a dietary supplement.
Citation Information
Patent Citations
Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
CN103764154A
Feed additive composition
CN104684408A
Composite probiotics capable of increasing survival rate of piglets
CN108371247A
Spore-Based Probiotic Composition for Reduction of Dietary Endotoxemia and Related Methods
US20180289752A1
